[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( [marketinside...] --------------------------------------------------------------- [Economic and National Security Threats Create Lithium Bonanza]( [Click here for the full story](.[aff_i?offer_...] --------------------------------------------------------------- September 14, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers of all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [The 800-lb Chinese Gorilla]( [5439d433-d80...](China consumes 54% of the world's copper. Yet China mines only 8% of its copper needs, while plundering Africa, Latin America and South America for copper. The U.S. is left scrambling for new copper sources. But there's a North American copper sweet spot overlooked by China – for now. [Find Out Where This Copper Hotspot Is and How You Can Benefit]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Terns Pharmaceuticals, TERN]( Recent Analyst Action: Ed Arce, analyst at H.C. Wainwright, reiterates coverage on [Terns Pharmaceuticals (TERN)](in the Healthcare sector with a Hold rating and a price target of $6.00 (2 days ago). - Recent Price: $6.71 - Average Analyst Price Target: $5.50 (-18.03%) - Market Cap: $238.85M [TipRanks.com]( also reports that [Terns Pharmaceuticals](currently has 2 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $5.50. The target pricing ranges from a high forecast of $6.00 down to a low forecast of $5.00. [Terns Pharmaceuticals (TERN)](’s last closing price was $6.71 which would put the average price target at $5.50. Here are 3rd party ratings for [TERN](: - TipRanks.com: Hold - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 29% (73 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast: ["Prepare for Five Years of Famine"]( [Screen+Shot+...]( [Click here]( for the name of the one ticker you need to protect yourself.[5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Eve Holding, EVEX]( Recent Analyst Action: Marvin Fong, analyst at BTIG, reiterates coverage on [Eve Holding (EVEX)](in the Financial sector with a Hold rating (1 month ago). - Recent Price: $9.68 - Average Analyst Price Target: $7.30 (-24.59%) - Market Cap: $2.30B [TipRanks.com]( also reports that [Eve Holding](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $7.30. The target pricing ranges from a high forecast of $7.30 down to a low forecast of $7.30. [Eve Holding (EVEX)](’s last closing price was $9.68 which would put the average price target at $7.30. Here are 3rd party ratings for [EVEX](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 38% (94 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Immuneering, IMRX]( Recent Analyst Action: Geulah Livshits, analyst at Chardan Capital, reiterates coverage on [Immuneering (IMRX)](in the Services sector with a Buy rating and a price target of $18.00 (1 month ago). - Recent Price: $13.39 - Average Analyst Price Target: $23.67 (76.77%) - Market Cap: $316.71M [TipRanks.com]( also reports that [Immuneering](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $23.67. The target pricing ranges from a high forecast of $41.00 down to a low forecast of $12.00. [Immuneering (IMRX)](’s last closing price was $13.39 which would put the average price target at $23.67. Here are 3rd party ratings for [IMRX](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Buy, Top 29% (73 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [These 2 Dividend Stocks Pay Every Week]( [bc82e8e3-d6f...](Are you still looking for consistent income in this near-zero interest rate environment? There is a better way. I just revealed the Holy Grail of dividend stocks - a safe, reliable and consistent stock that [pays dividends EVERY single week](- 52 times a year. It's simple: Buy the stock this Monday and you'll get your first dividend payout in your bank account this Thursday....and then every Thursday after for as long as you own the stock! [Tap here to reveal the name of this stock for FREE.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Regulus, RGLS]( Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on [Regulus (RGLS)](in the Healthcare sector with a Buy rating and a price target of $20.00 (4 weeks ago). - Recent Price: $2.185 - Average Analyst Price Target: $20.00 (815.33%) - Market Cap: $31.24M [TipRanks.com]( also reports that [Regulus](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $20.00. The target pricing ranges from a high forecast of $20.00 down to a low forecast of $20.00. [Regulus (RGLS)](’s last closing price was $2.185 which would put the average price target at $20.00. Here are 3rd party ratings for [RGLS](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Sell, Top 36% (89 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Protara Therapeutics, TARA]( Recent Analyst Action: Andrew Fein, analyst at H.C. Wainwright, reiterates coverage on [Protara Therapeutics (TARA)](in the Healthcare sector with a Buy rating and a price target of $23.00 (1 month ago). - Recent Price: $4.2 - Average Analyst Price Target: $23.00 (447.62%) - Market Cap: $48.11M [TipRanks.com]( also reports that [Protara Therapeutics](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $23.00. The target pricing ranges from a high forecast of $23.00 down to a low forecast of $23.00. [Protara Therapeutics (TARA)](’s last closing price was $4.2 which would put the average price target at $23.00. Here are 3rd party ratings for [TARA](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 36% (89 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing]( [c4145ddb-c97...](The White House is scared of our country's lithium supply running out. That's why Biden issued executive order 14017 to figure out how to expand our lithium production. And this is GREAT news for one company who's gobbling up land in the lithium-rich Nevada desert. [See How Order 14017 Could Send This Company Skyrocketing]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Brainstorm Cell Therapeutics, BCLI]( Recent Analyst Action: Jason McCarthy, analyst at Maxim Group, reiterates coverage on [Brainstorm Cell Therapeutics (BCLI)](in the Healthcare sector with a Buy rating and a price target of $8.00 (4 weeks ago). - Recent Price: $4.22 - Average Analyst Price Target: $8.00 (89.57%) - Market Cap: $148.13M [TipRanks.com]( also reports that [Brainstorm Cell Therapeutics](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.00. The target pricing ranges from a high forecast of $8.00 down to a low forecast of $8.00. [Brainstorm Cell Therapeutics (BCLI)](’s last closing price was $4.22 which would put the average price target at $8.00. Here are 3rd party ratings for [BCLI](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: n/a, n/a [Click here for chart >>]( -------------------------------------------------------------------------- [Pyxis Tankers, PXS]( Recent Analyst Action: James Jang, analyst at Univest Securities, reiterates coverage on [Pyxis Tankers (PXS)](in the Industrial Goods sector with a Buy rating and a price target of $8.00 (1 day ago). - Recent Price: $4.08 - Average Analyst Price Target: $8.00 (96.08%) - Market Cap: $41.08M [TipRanks.com]( also reports that [Pyxis Tankers](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.00. The target pricing ranges from a high forecast of $8.00 down to a low forecast of $8.00. [Pyxis Tankers (PXS)](’s last closing price was $4.08 which would put the average price target at $8.00. Here are 3rd party ratings for [PXS](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 16% (41 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- ["The Most Critical Metal for Global Economies"]( [e33a456c-e65...](The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year. [Find Out How This Is Good News for Commodity Investors.]( //trailer.web-view.net/Links/0XB8A858C3726E83F267653612586B6FA86F15B8BA7DEB4A7A6038EBCC118DF015FBC79A20E2EF6263C69C50C7F368F8BB236C08A624882BD1001B444F7491C4D0F598CD369566B7DD.htm [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- And there you have it--7 Five Day Gainers of all US Exchanges. Sincerely, Editor, MarketInsidersPress.com Market Insider Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 Sandpiper Marketing Group, LLC | 165 Lockerbie Lane | Moorsville | North Carolina | 28115 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software